Exact Sciences' Non-Invasive Colorectal Cancer Test Could Have Big Impact, says CEO Conroy Print E-mail
By Staff and Wire Reports   
Tuesday, 06 March 2012 00:00
interviewExact Sciences Corporation, the molecular diagnostics company focused on colorectal cancer has been steadily inching towards their commercialization goals and one need only look at their stock chart to see the steady, reliable advancement.

Inch by inch, shares of the company have been progressively climbing since we began covering it in early 2009.  Based in Madison, Wisconsin, Exact Sciences was incorporated in February 1995, with a vision to develop a molecular diagnostic colorectal cancer screening test that detects both cancer and pre-cancer. Now, if things go as planned, Exact Sciences should be launching the Cologuard test within two years.

"Exact Sciences is a company that is totally focused on the early detection of colorectal cancer," explains Kevin T. Conroy who was named President and Chief Executive Officer of Exact Sciences in April 2009. "In the U.S. there are one hundred and forty thousand new cases of colon cancer every year and fifty thousand deaths. This is the cancer that is known as the most preventable cancer. We think a non-invasive test that is easy to use and patient friendly could have a big impact at being able to detect disease early."

Exact Sciences' non-invasive stool-based DNA (sDNA) test provides an additional tool for cancer screening that allows for early detection of the disease state. The company is engaged in developing an investigational device for the detection of both cancer and pre-cancers by combining methylation markers, mutation markers and a fecal immunochemical test (FIT).

In a video interview, Conroy explains the firm's plans in detail and shares his thoughts on how the test could have an impact on the entire field of colorectal cancer screening.







"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter